• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Dr. Mark Stetter Elected to Zoetis Board of Directors

    5/22/25 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZTS alert in real time by email

    Dean of the University of California, Davis School of Veterinary Medicine brings extensive and valuable experience in animal health to Zoetis Board

    Zoetis Inc. (NYSE:ZTS) today announced the election of Dr. Mark Stetter to its Board of Directors, effective as of the company's annual shareholder meeting on May 21, 2025.

    Dr. Stetter brings extensive experience in veterinary medicine and animal health, including as Dean of the University of California, Davis School of Veterinary Medicine, to the Zoetis Board. His career in animal health includes pets, livestock, exotic animals, research and wildlife. He will serve on the Board's Quality and Innovation Committee.

    "Dr. Stetter brings invaluable real-world experience in animal health to our Board," said Kristin Peck, Chief Executive Officer of Zoetis. "Our customers are at the heart of everything we do and leveraging Mark's experiences and insights will help us continue to adapt and innovate to best serve them. We're thrilled to have him join our Board as we continue to live our purpose of advancing care for animals."

    "We are pleased to welcome Dr. Mark Stetter to Zoetis' Board of Directors, and we look forward to the contributions he will make as we continue to advance the animal health industry and deliver innovation to our customers," said Zoetis Board Chair Michael McCallister.

    Dr. Stetter has served as Dean of the University of California, Davis School of Veterinary Medicine since 2021. In this role he oversees all aspects of the school including education, research, veterinary hospitals, animal health diagnostic labs, centers and institutes. He was Dean and Professor at the College of Veterinary Medicine and Biomedical Sciences at Colorado State University from 2012 until 2021. Prior to joining higher education, Dr. Stetter held various roles at The Walt Disney Company, The Bronx Zoo/Wildlife Conservation Society and the Audubon Nature Institute. Dr. Stetter holds a Doctor of Veterinary Medicine and a Bachelor of Science degree in biochemistry and chemistry from the University of Illinois at Champaign-Urbana.

    "I am incredibly grateful for the opportunity to join Zoetis' Board of Directors," said Dr. Mark Stetter. "As a veterinarian I've seen firsthand the impact the company's innovative products have on animals, and I look forward to bringing my professional expertise and passion for animal health to Zoetis as they continue to advance care for the industry."

    About Zoetis

    As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock producers. The company's leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $9.3 billion in 2024 with approximately 13,800 employees. For more information, visit www.zoetis.com.

    ZTS-COR

    ZTS-IR

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250521581265/en/

    Media:

    Jennifer Albano

    1-862-399-0810 (o)

    [email protected]



    Laura Panza

    1-973-975-5176 (o)

    [email protected]



    Investor:

    Steve Frank

    1-973-822-7141 (o)

    [email protected]



    Nick Soonthornchai

    1-973-443-2792 (o)

    [email protected]

    Get the next $ZTS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZTS

    DatePrice TargetRatingAnalyst
    6/18/2025$160.00Buy → Hold
    Stifel
    12/2/2024$215.00Outperform
    Leerink Partners
    7/25/2024$220.00Buy
    BTIG Research
    1/12/2024$195.00 → $215.00Buy
    Stifel
    12/19/2023$230.00Buy
    Jefferies
    12/7/2023$237.00Outperform
    Exane BNP Paribas
    9/6/2023$230.00Buy
    HSBC Securities
    7/12/2022$205.00Overweight
    Piper Sandler
    More analyst ratings

    $ZTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Executive Vice President Lagano Roxanne sold $110,840 worth of shares (652 units at $170.00), decreasing direct ownership by 4% to 15,129 units (SEC Form 4)

      4 - Zoetis Inc. (0001555280) (Issuer)

      6/4/25 4:31:39 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Scully Robert W converted options into 17,535 shares, increasing direct ownership by 443% to 21,489 units (SEC Form 4)

      4 - Zoetis Inc. (0001555280) (Issuer)

      5/23/25 12:14:50 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Stetter Mark

      4 - Zoetis Inc. (0001555280) (Issuer)

      5/22/25 6:32:13 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Zoetis downgraded by Stifel with a new price target

      Stifel downgraded Zoetis from Buy to Hold and set a new price target of $160.00

      6/18/25 7:45:54 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Zoetis with a new price target

      Leerink Partners initiated coverage of Zoetis with a rating of Outperform and set a new price target of $215.00

      12/2/24 7:04:18 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Zoetis with a new price target

      BTIG Research initiated coverage of Zoetis with a rating of Buy and set a new price target of $220.00

      7/25/24 6:48:19 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care